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Abstract
5-Aminoimidazole-4-carboxamide-1-b-4-ribofuranoside (AICAR), an analog of AMP is widely used as an activator of AMP-
kinase (AMPK), a protein that regulates the responses of the cell to energy change. Recently, we showed that AICAR-induced
AMPK activation inhibits the growth of retinoblastoma cells in vitro by decreasing cyclins and by inducing apoptosis and S-
phase arrest. In this study, we investigated the effects of AMPK activator AICAR on the growth of retinoblastoma in vivo.
Intraperitoneal injection of AICAR resulted in 48% growth inhibition of Y79 retinoblastoma cell tumors in mice. Tumors
isolated from mice treated with AICAR had decreased expression of Ki67 and increased apoptotic cells (TUNEL positive)
compared with the control. In addition, AICAR treatment suppressed significantly tumor vessel density and macrophage
infiltration. We also showed that AICAR administration resulted in AMPK activation and mTOR pathway inhibition.
Paradoxically observed down-regulation of p21, which indicates that p21 may have a novel function of an oncogene in
retinoblastoma tumor. Our results indicate that AICAR treatment inhibited the growth of retinoblastoma tumor in vivo via
AMPK/mTORC1 pathway and by apoptogenic, anti-proliferative, anti-angiogenesis mechanism. AICAR is a promising novel
non-chemotherapeutic drug that may be effective as an adjuvant in treating Retinoblastoma.
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Introduction
Retinoblastoma is the most common primary malignant
intraocular tumor in infants and children. In USA it affects 12
per million children aged 0–4 years, representing 6.1% of all
childhood cancers under the age of 5 years [1]. Slightly more than
half of the patients have the sporadic or non-inherited form of the
disease, which results from the spontaneous inactivation of the
retinoblastoma gene (RB1). In the heritable form, the patient
inherits usually one defective gene from the parents and a
subsequent ‘‘hit’’ of the uninvolved gene results in tumor
formation. The heritable form is more often bilateral than the
non-heritable form of the disease. Despite progress in the
treatment of retinoblastoma [2], significant problems remain
unsolved. Metastatic disease is often fatal [3]. Although several
treatments are available for retinoblastoma, including enucleation
and/or combination of chemotherapy, laser and cryotherapy,
each of them has major drawbacks in pediatric patients.
Conventional external beam radiation, which is used today to
control large tumors, has many complications, including an
increased appearance of secondary malignancies, such as osteo-
sarcoma. This complication occurs more frequently in patients
with hereditary retinoblastoma. The 30-year cumulative incidence
of second malignancies is .35% for patients who received
external beam therapy vs 6% for those patients without radiation
[4]. Systemic chemotherapy used as a first line treatment for
intraocular retinoblastoma with subsequent consolidation with
photocoagulation, cryotherapy, or radiotherapy has a recurrence
rate of 24% by 5 years [5]. This increases to 50% for patients with
vitreous seeds [6]. Most recently analysis by the Shields and
Murray groups [6,7] show success for local control approaching
99% for RE stage I–IV, but ,80% for RE stage V, and 90–100%
for group A–C, but in less than 50% for group D (new
international classification). In addition, significant morbidity with
the chemotherapy has been described previously [8]. One of the
drugs used for chemotherapy (etoposide) is thought to be
associated with increased incidence of acute myeloblastic leukemia
although the actual cases implicated so far have been low with
,20 cases reported [9]. For these reasons, there is a need for
alternative new treatment modalities for retinoblastoma with
better safety and efficacy profile.
5-Aminoimidazole- 4- carboxamide riboside (AICAR) is widely
used as a pharmacologic activator of AMP-activated protein
kinase (AMPK). AMPK is a heterotrimeric serine/threonine
protein kinase [10], which acts as a sensor of cellular energy
levels and stress. Several metabolic stresses, including hypoxia,
exercise, ischemia, heat shock and long-term starvation, regulate
its activity [11–14]. Its upstream protein kinase LKB1 [15,16] is
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syndrome [17]. Downstream effectors of AMPK also involve the
tumor suppressor Tuberous Sclerosis Complex (TSC2) and the
mammalian target of Rapamycin (mTOR). Both are important
known factors in cell cycle progression and tumor formation
[18,19]. AICAR is taken into cells and converted to the
monophosphorylated form ZMP, mimicking an increase of AMP
intracellular levels [20]. AICAR has low or no apparent toxicity
and has been shown to be a great in vivo exercise mimetic [21].
Many studies have shown that AICAR can inhibit proliferation,
and induce apoptosis in multiple myeloma cells [22], neuroblas-
toma cells [23], glioblastoma cells [24], childhood acute lympho-
blastic leukemia (ALL) cells [25] colon cancer cells [26] and breast
and prostate cancer cell lines [27].
We have recently demonstrated that AICAR was an efficient
inhibitor of retinoblastoma cell proliferation in vitro through S-
phase arrest, decrease of cyclins A and E, and partial inhibition of
the mTOR pathway [28]. In the present study, we examined the
in vivo effects of AICAR on Y79 Rb cell growth and demonstrated
that AICAR significantly inhibited the growth of tumors in nude
mice xenotransplants, by inducing apoptosis and suppressing
tumor angiogenesis and macrophage infiltration.
Materials and Methods
Chemicals and Cell Culture
AICAR was purchased from Sigma Aldrich, St.Louis, MO,
USA. AICAR was dissolved in Phosphate Buffered Saline (PBS) at
concentration 67 mg/ml (260 mM) (stock solution) and stored at
220uC until utilization. The human retinoblastoma cells Y79
(ATCC, Manassas, VA, USA) were grown in RPMI medium
(RPMI 1640 medium), supplemented with 20% fetal bovine serum
(FBS) (Invitrogen), penicillin (100 mg/ml) –streptomycin (100 mg/
ml) (Invitrogen), 2 mM l-glutamine (Invitrogen) and 10 mM
HEPES (Invitrogen). Cells were incubated at 37uC in a humidified
atmosphere of 95% air and 5% CO2 and split when the cells
reached approximately 90% confluence.
Animals
All animal experiments complied with the Association for
Research in Vision and Ophthalmology for the use of animals in
ophthalmic and vision research and were approved by the Animal
Care and Use Committee of the Massachusetts Eye and Ear
Infirmary (Ref #196524) (Boston, MA, USA). Four to six-week-
old BALB/c (nu/nu) female mice were purchased from Charles
River Laboratories (MA) and maintained in a facility under
specific pathogen-free conditions. The animals were fed with
pathogen free laboratory chow and allowed free access to
autoclaved water in an air-conditioned room with a 12 h light/
dark cycle.
Xenograft tumor growth assay
The xenografted tumors were established by a single subcuta-
neous injection in each of the two flanks of 4610
6 Y79
retinoblastoma cells in 0.3 ml of a 1:1 mixture of ice-cold matrigel
basement membrane matrix (BD Bioscience, MA, USA) and
RPMI 1640 medium supplemented with 20% FBS. Once a tumor
mass became visible, three days after the injection of the cells, the
mice were randomized into two groups with five mice in each
group: one group receiving peritoneal injections of 500 mg/kg
AICAR, the other group receiving equal volume normal saline.
Mice received an injection every twenty-four hours for 28 days in
total. The tumor volume was monitored by external measurement
in two dimensions with calipers every other day. Tumor volume
was determined according to the equation: volume (mm
3)=4/
36p6(length/2)6(width/2)
2, described by Miyano-Kurosaki et al
[29]. Four weeks after the first injection of AICAR, the mice were
anesthetized and tumors were dissected, weighed, and stored at
280uC for further analysis.. The tumor inhibition ratio was
calculated as follows: inhibition ratio (%)=[(C2T)/C]6100%,
where C is the average tumor weight (or volume) of the control
group and T is the average tumor weight (or volume) of the
AICAR treated group. The experiment was performed on 3
independent times each time with 5 mice in each group.
Immunohistochemistry assay and pathological
evaluation
Five representative frozen tumors from each group were
analyzed for retinoblastoma cell proliferation, vessel area, and
macrophage infiltration. Frozen tissues were cut into 10-mm
sections, fixed in 4% paraformaldehyde at room temperature for
10 min, blocked for one hour, and treated with goat serum.
Tumor sections were incubated all night in a humid chamber at
4uC with primary monoclonal antibodies, including anti-Ki67
(dilution 1:100, Dako), anti-CD31 (dilution 1:100, BD Bioscience)
and anti-CD11b (dilution 1:100, BD Bioscience). An appropriate
fluorophore-conjugated secondary antibody (Molecular Probes,
Carlsbad, CA) was used to detect fluorescence using a confocal
microscope (Leica Microsystems, Wetzler, Germany). Nuclei were
stained with propidium iodide (PI), in the staining assay for Ki67,
and with 49, 6-diamidino-2-phenylindole (DAPI), in the staining
assay for CD11b and CD31. Cryostat sections of each tumor
xenograft were stained, four different fields at 620 magnification
were examined on each section and the percentage of fluorescent-
positive cells/PI-positive cells or DAPI-positive cells in each field
was measured. Tumor vessel area was calculated as the number of
image pixels stained positive with CD31 per high-power field. In
negative-control staining, the primary antibodies were omitted.
TUNEL Analysis
To determine the degree of apoptosis, cryostat sections were
prepared from tumor xenografts 31 days after implantation.
Terminal dUTP nick-end labeling (TUNEL) assay was performed
using the ApopTag Fluorescein In Situ Apoptosis Detection Kit
(S7110, Chemicon International, Temecula, CA). Nuclei were
stained with propidium iodide. The number of TUNEL (+) cells
was counted in four randomly selected fields of each section from
all tumor xenografts at 620 magnification using confocal
microscope.
Protein extraction
Twelve control tumors and twelve AICAR treated tumors were
chosen for analysis. The tumors were mechanically disrupted in
liquid nitrogen and pieces were weighted and transferred into the
pre-cooled T-PER Mammalian Protein Extraction Reagent
(Thermo-Scientific, Pierce Protein Research Products) with freshly
added protease (according to manufacturer suggestions; Roche
Applied Science) and phosphatase inhibitor cocktails (dilution
1:50; Thermo-Scientific, Pierce Protein Research Products). The
pieces were homogenized for 15 s using rotor - stator and
incubated on ice for 30 min with intermittent vortexing every
5 min. Then the samples were centrifuged for 15 min with speed
13 000 rpm in +4uC degrees. Supernatant was collected. The
extraction was performed twice each time from multiple random
areas of each tumor (from 12 tumors n=24 samples analyzed).
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The LDS sample buffer (1:4; Invitrogen), containing 2
microliters of 2-mercaptoethanol (Cambrex), was added to each
sample. The samples were incubated at 95uC for 5 min and
centrifuged briefly. Ten micrograms of total amount of proteins
and thirty microliters of each sample per lane was loaded onto a 4–
12% Bis-Tris Gel (NuPAGE; Invitrogen). The electrophoresis was
done using NuPAGE MOPS or NuPAGE MES Running Buffer
for proteins .25 kDa or ,25 kDa respectively (Invitrogen) and
then samples were transferred onto a PVDF membrane (0.2
micrometer; Millipore, Billerica, MA, USA). The membranes
were cut and blocked for 1 h at room temperature in 5% wt/vol
BSA, 1xTBS 0.05% Tween 20 at gentle shaking. The following
primary anti-human monoclonal antibodies were used: p21 Waf1/
Cip1 (12D1) and phospho-4E-BP1 (Ser-65) from Cell-Signaling
Technology (Danvers, MA, USA), phospho-ACC (Ser-79) and
phospho-S6 ribosomal protein (Ser-235/236) from Epitomics
(Burlingame, CA, USA). Antihuman monoclonal GAPDH anti-
body from Epitomics was used as a loading control (Burlingame,
CA, USA). The antibodies were diluted in 5% wt/vol BSA
1xTBS, 0.1% Tween20 as follows: p21 Waf1/Cip1 (1:1000),
phospho-4E-BP1 (1:1000), phospho-S6 ribosomal protein
(1:20,000), p-ACC (1:10,000) and GAPDH (1:10,000). The blotted
membranes were incubated at 4uC with gentle shaking. The
following day the membranes were washed 3 times (5 min) with
TBS 0.1% Tween 20 and incubated for 1 hour at room
temperature with the horseradish peroxidase-labeled secondary
antibodies in dilution 1:1000 (goat antirabbit, Cell Signaling
Technology, Danvers, MA, USA). The membranes were washed 3
times (5 min) in TBS 0.1% Tween 20. The immunoreactive bands
were visualized with ECL or ECLprime and exposured onto Fuji
RX film (Fujifilm,Tokyo, Japan). The results were quantified using
ImageJ software. GAPDH was used as internal control.
Quantitative real-time RT-PCR
Eight control tumors and eight AICAR treated tumors were
chosen for qRT-PCR analysis. The tumors were mechanically
disrupted in liquid nitrogen and pieces were weighted. RNA was
extracted and purified with the RNeasy Midi kit (Qiagen,
Valencia, CA, USA). RNA was further cleaned with an additional
DNase I digestion step, according to the manufacturer’s instruc-
tions. The concentration and quality of RNA was assessed using
Nanodrop software and only RNA with both A260/A280 and
A260/A230 .2 were selected for further analysis. Reverse
transcription was performed for equal RNA amounts (4 micro-
grams) with OligodT primer (Invitrogen) and Superscript II
(Invitrogen). cDNA 50 ng for all (except CCNE2 2100 ng,
CCNA1 2200 ng) was used for each of the 4 replicates for
quantitative RT-PCR. The human cyclins: A1, A2, E1, E2, D1,
D2 were amplified with commercially designed exon spanning
Taqman gene expression assays (Applied Biosystems, Foster City,
CA, USA) and the Taqman universal PCR master mix (Applied
Biosystems). GADPH, ACTB and TBP were used as independent
endogenous controls. The results were acquired with a Step One
Plus real-time PCR system (Applied Biosystems) and the data was
calculated using comparative method described by Livek at al
[30]. The extraction was performed twice each time from multiple
random areas of each tumor (from 8 tumors, n=16 samples
analyzed).
Statistical Analysis
The data are expressed as mean 6 SEM (standard error of the
mean). Statistical significance was evaluated using the unpaired
Student’s t-test and defined as P#0.05 (*), P#0.01 (**) or P#0.001
(***). Two-tailed tests were used for all comparisons. The data
were expressed as mean 6 SEM.
Results
AICAR suppresses growth of human retinoblastoma
xenografts
To evaluate the in vivo effect of AICAR on retinoblastoma
growth, heterotopic tumor xenografts of human Y79 retinoblas-
toma cells were established and treated with AICAR (500 mg/kg/
day, I.P.) or PBS. The appearance of the mice 28 days after
treatment with or without AICAR is shown in Figure 1. In the
mice treated with vehicle, large tumors were present where the
Y79 cells were implanted whereas much less sizable tumors were
seen in AICAR treated animals (Figure 1A,B). Compared to the
PBS-treated group, AICAR suppressed tumor volume growth by
47% (p,0.03, n=10, Figure 1C). The mean tumor weight,
determined at necropsy, in the control mice was 1.5360.32 g, as
compared to 0.9260.14 g in the AICAR-treated mice (Figure 1D)
(n=10, p,0.05). Similar results were seen if treatment was started
12 or 19 days later. The body weight of the mice was recorded bi-
weekly and was not found to differ significantly among the groups
(p=0.67, Figure 1E).
AICAR reduces human retinoblastoma Y79 cell
proliferation and induces apoptosis
To evaluate the in vivo proliferation ability of retinoblastoma
cells, we examined the expression of Ki67 in four different areas
from a section of five control tumors and five AICAR-treated
Figure 1. AICAR inhibited growth of xenografted tumors of
Y79 human retinoblastoma cells in Nu/Nu immune-deficient
mice. Human retinoblastoma Y79 cell heterotopic transplanted tumors
were developed as described in Materials and Methods. Mice were
treated with AICAR for 28 days. Tumor growth was monitored, and
tumor tissues were collected and weighed on the 28th day after the
first injection of AICAR. (A and B) Macroscopic appearance of the mice
31 days after transplantation of Y79 cells, without AICAR (A) and with
500 mg/kg/day AICAR (B). (C) Tumor growth curves: mean volumes of
PBS- vs AICAR-treated group on days indicated. (D) Mean weights of
tumors at autopsy of mice treated with PBS (empty column) or AICAR
(filled column). (E) Effect of AICAR on body weight of mice transplanted
with Y79 cells. Body weight of mice transplanted with Y79 cells with or
without 500 mg/kg/day AICAR treatment was pursued for 31 days. Data
are presented as mean 6 SEM (n=10).*p,0.05.
doi:10.1371/journal.pone.0052852.g001
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double staining of the cells with Ki67 and PI in the frozen sections
from each tumor. The average Ki67(+)/PI(+) cells ratio was
12.44% in control mice, while it was 2.31% in AICAR-treated
mice (p,0.001), showing that the proliferation ability of the cells
in AICAR-treated mice was much reduced compared with the
control-treated mice (Figure 2C). Apoptotic cells, with the
morphology of a condensed cytoplasm and pyknotic hyperchro-
matic nuclei, were numerous in the sections of the tumor
xenografts. To quantify the apoptotic cells in AICAR-treated
and control tumors, frozen sections from each tumor were
analyzed using the TUNEL assay. Figure 2E shows a typical
image of the apoptotic cells with TUNEL staining in the AICAR-
treated tumor. In contrast, an image of a control tumor shows
significantly fewer apoptotic cells (Figure 2D). Figure 2F shows
that the average number of apoptotic cells/PI(+) cells in the
AICAR-treated tumors was 49.97%, as compared with 8.17% in
the control tumors, representing an ,6-fold increase (p,0.001).
AICAR inhibits tumor angiogenesis
The effect of AICAR on tumor angiogenesis was evaluated by
CD31 immunofluorescence staining for capillaries in tumor
tissues. The amount of CD31-stained tumor capillaries in the
AICAR-treated group was less than in the PBS-treated group
(Figure 3A,B). Morphometric analysis revealed that the microves-
sel density (MVD) of the AICAR-treated group was significantly
reduced compared to the PBS-treated group (p=0.003,
Figure 3C). These data demonstrate that AICAR inhibits the
neovascularization of retinoblastoma.
AICAR down-regulates infiltration by CD11b(+)
inflammatory cells
Inflammatory cells such as neutrophils and macrophages are
thought to play an important role in tumor progression.
Therefore, we analyzed the content of inflammatory cells
populating tumors in the AICAR-treated group and the PBS-
treated group. Interestingly, large differences were observed in the
number of the CD11b(+) tumor-infiltrating neutrophils between
the two groups (Figure 3D,E). Tumors isolated from AICAR-
treated mice exhibited significantly lower contents of CD11b(+)
cells than tumors from control mice (p=0.002, Figure 3,D–F).
Antiproliferative effects of AICAR are associated with
activation of the AMPK pathway and inhibition of the
mTORC1 pathway
To determine whether AICAR treatment in vivo was associated
with AMPK activation as was observed in our in vitro study [28],
we evaluated by Western blotting the phosphorylation of the
immediate downstream target of AMPK, acetyl-CoA carboxylase
(ACC) [31]. AICAR treated group had a 36% increase in the
phosphorylation levels of ACC compared to controls (p,0.007,
n=19, Figure 4A) suggesting activation of the AMPK pathway. It
has been well established that AMPK activation leads to inhibition
of the mTOR pathway, resulting in dephosphorylation of
ribosomal protein S6 that causes decreased initiation of translation
and protein synthesis [32–34]. Thus we next examined the effects
of AICAR on the activity of the mTOR pathway by Western blot
analysis of retinoblastoma xenografts extracts. We assessed the
phosphorylation status of two direct downstream targets of mTOR
pathway, ribosomal S6 protein (Ser235/236) and the 4E-BP1
(Ser65) as a measure of mTOR activity. As expected, AICAR
Figure 2. AICAR suppressed proliferation and induced apoptosis of retinoblastoma in vivo. (A, B) Immunofluorescent analysis for Ki67 of
tumors of Y79 cells isolated from control mice (A) and AICAR-treated mice (B). Nuclei were stained with propidium iodide (red). (C) Quantitative
analysis of Ki67 (+) cells/PI (+) cells ratio in tumors. Values are significantly lower in the AICAR-treated mice group than in the control mice group
(**p,0.01). (D,E) Apoptotic cells in retinoblastoma xenografts. Typical photomicrographs of apoptotic cells using TUNEL assay (green) in Y79
xenografts. Nuclei were stained with propidium iodide (red). Y79 cells isolated from control mice (D) and AICAR-treated mice (E). (F) Quantitative
analysis of the apoptotic cell percentage in tumors. Note that the number of TUNEL (+) cells was significantly higher in the AICAR-treated mice group
than in the control mice group (**p,0.01). Each column represents the mean 6 SEM. Scale bars (A, B, D, E), 200 mm.
doi:10.1371/journal.pone.0052852.g002
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ribosomal S6 protein (49% vs 100%, p,0.001, n=17, Figure 4B)
and its downstream effector, 4E-BP1 when comparing to control
(43% vs 100%, p,0.001, n=23, Figure 4C). These results suggest
that AICAR inhibits mTORC1 signaling in retinoblastoma in vivo
mouse model.
In vivo AICAR treatment does not affect the levels of the
cyclins A, E, D in retinoblastoma, while it is associated
with down-regulation of p21
Progression of the cell cycle in eukaryotic cells is regulated by a
series of serine/threonine protein kinases which consist of a
catalytic subunits, cyclin dependent kinases (CDKs), and a
regulatory subunits, cyclins [35]. Given the effect of AICAR on
the cell cycle [28], we wanted to see whether that was mediated by
changes in the levels of the appropriate cyclins. In contrast to our
previous study [28], treatment with AICAR showed no change in
the levels of mRNA levels of cyclins A, E, D when compared to
control (n=14; Figure 5). Interestingly, similar to our previous in
vitro study [28] and in contrast to studies in other cell lines
[20,36,37], AICAR down-regulated the protein levels of the
cyclin-dependent kinase inhibitor p21 (also known as p21WAF1/
Cip1) (67% vs 100%, p,0.02, n=23; Figure 4D). Thus our in
vivo and in vitro data suggest that p21 may have a unique role in
regulating retinoblastoma tumor and could possibly function as an
oncogene.
Discussion
AICAR has been shown to be an exercise mimetic [21] and to
have anti-cancer properties [20,22–28]. The mechanisms respon-
sible for these effects are not fully understood but they likely
involve activation of AMPK. Our previous study showed that
AICAR inhibits the growth of human retinoblastoma cells in vitro
through inhibition of the mTOR pathway, down-regulation of
cyclins A and E, and through inhibition of p21, which in
retinoblastoma cells may act as an oncogene [28]. In the present
study, we examined the inhibitory effects of AICAR on the growth
of retinoblastoma xenografts in vivo. The growth of the
retinoblastoma Y79 cells transplanted in nude mice was exten-
sively suppressed and the size of tumor decreased to almost half of
the control, after four weeks of AICAR administration (Figure 1).
These results are consistent with previous reports on the in vivo
anti-tumor effect of AICAR on glioblastoma, breast cancer and
glioma xenografts [20,24,27] and suggest a potential non-
chemotherapeutic strategy for retinoblastoma.
Recent studies demonstrated that AICAR inhibited cancer cells
in vivo by inducing apoptosis [20] or through cytostatic
mechanism [24]. We found that that the tumor mass of Y79
transplanted into nude mice treated with AICAR contained an
increased number of apoptotic cells (Figure 2F) and cells with
decreased mitotic figures, which may be attributed to the
apoptogenic and antiproliferative activity of AICAR in vivo. A
decreased Ki67 value in the masses of Y79 tumor of the mice
treated with AICAR (Figure 2C) also suggested that the
proliferation of the tumor was suppressed by AICAR, because
Ki67 has been considered a good marker to evaluate the
proliferation ability of cancers, especially of recurrent cancers [38].
Angiogenesis, the growth of new blood vessels from preexisting
capillaries, is necessary for solid tumor growth and metastasis
[39,40]. Anti-angiogenesis therapy provides a novel approach for
cancer management [39]. Retinoblastoma, originating from
retina, maintains itself from retinal vasculature initially, and as
the tumor grows and outstrips the retina, neovascularization in
Figure 3. AICAR suppressed tumor angiogenesis and inflammatory cells infiltration. (A, B) Microvessel density in tumor tissues was
determined by immunofluorescent staining by an endothelial-specific antibody CD31. (A) Control group and (B) AICAR-treated group. (C)
Quantitative analysis of fluorescent-positive area (per 4000 mm
2) in tumors. Vessel density was significantly suppressed in AICAR-treated mice group
(**p,0.01). (D, E) Macrophage- and neutrophil- infiltration in Y79 xenografts. Typical photomicrographs of immunofluorescent staining for CD11b
(red) in Y79 xenografts. Nuclei were stained with propidium iodide (blue). Y79 cells isolated from control mice (D) and AICAR-treated mice (E). (F)
Quantitative analysis of the CD11b (+) cells/DAPI (+) cells ratio in tumors. The number of CD11b (+) cells was significantly lower in the AICAR-treated
mice group than in the control mice group (**p,0.01). Each column represents the mean 6 SEM. Scale bars (A, B, D, E), 200 mm.
doi:10.1371/journal.pone.0052852.g003
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malignant progression. Studies have shown that inhibition of the
angiogenesis of retinoblastoma could be a new strategy for
retinoblastoma therapy [41]. In the present study, we reported
for the first time that intraperitoneal injection of AICAR inhibited
retinoblastoma growth in xenografted mice and that vessel density
in tumor tissues was decreased by AICAR (Figure 3A–C). In
addition, AICAR suppressed macrophage infiltration (Figure 3D–
F). The last result may be a reflection of less vessel infiltration or a
result of less overall inflammation, as AICAR has been shown to
have anti-inflammatory properties [42–44]
Studies have shown that VEGF is highly expressed in
retinoblastoma [45] and that transfection of VEGF siRNA to
retinoblastoma cells led to the inhibition of tumor growth via
reduction in neovascularization [46]. In other studies AICAR and
activation of AMPK has been related with cytoprotection and
stimulation of angiogenesis in situations of ischemia/re-perfusion
injury [47,48]. The decrease in angiogenesis by AICAR may be an
indirect effect of the decreased tumor mass rather than a direct
effect on angiogenesis. AMPK stimulating angiogenesis under
ischemia condition [47,48] may be related to its protective effect
on endothelial cells in stress. The inhibition of angiogenesis in
cancer may be attributed to its effects on production and secretion
of cytokines. Recently, Zhou et al [49] reported that AMPK
upregulates TNFSF15, a cytokine that exerts a potent inhibitory
effect on tumor angiogenesis. It is, also, possible that the various
effects of AICAR depend on the specific cell type, cellular events
following external stimuli, paracrine effects and/or downstream-
regulated pathways.
Proliferation of cancer cells requires oncogenic growth signals as
well as sufficient metabolic energy for biogenesis of cellular
constituents [50]. The ‘‘Warburg effect’’ [51], a metabolic
derangement in cancer cells resulting in increased glucose uptake
Figure 4. AICAR treatment of retinoblastoma is associated with activation of AMPK, inhibition of mTORC1 and decrease of p21. A.
AICAR treatment of retinoblastoma is associated with activation of AMPK. Western blot analysis of phosphorylated ACC (Ser-79) (a downstream
effector of AMPK) showed significant increase of pACC in tumours from AICAR treated mice comparing to control (**p,0.01, n=19). B and C.
Treatment with AICAR resulted in the inhibition of the mTORC1 pathway. Western blot analysis of tumor xenografts harvested from mice treated with
AICAR showed significant decrease of mTOR pathway downstreams, pS6RP (Ser235/236) and the p4E-BP1 (Ser65) when compared to PBS-treated
mice (***p,0.001 for both, n=17 for pS6RP and n=23 for p4EBP1). D. AICAR down-regulates p21WAF1/Cip1 in AICAR treated tumors as shown via
Western blot analysis (*p,0.05, n=23). Density values bands are graphically expressed relative to control. GAPDH was used as a loading control in all
panels. Multiple bands represent separate biological samples. Each column represents the mean 6 SEM.
doi:10.1371/journal.pone.0052852.g004
Figure 5. AICAR does not alter the levels of cyclins A, D and E in
retinoblastoma in vivo. Quantitative RT-PCR analysis of tumors
treated with AICAR in comparison with control shows no significant
difference. Each column represents the mean 6 SEM.
doi:10.1371/journal.pone.0052852.g005
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ating tumor cells by supplying cellular bioenergetics required to
support tumor progression. Cells must coordinate diverse
processes including cell division, cell migration, and cell polarity
with the cell’s metabolic status. AMPK is posited to function as a
central sensor/regulator of energy status within the cell, and could
thus have direct roles in linking metabolism to cell division [34]. It
can interface with diverse signaling molecules ranging from LKB1
to mammalian target of rapamycin [34]. The mTORC1 is directly
inhibited by phosphorylation of raptor as a consequence of
activation of the AMPK [52]. The mTOR kinase pathway
regulate translation repressor protein (4EBP1) activity in vivo
[53,54] via phosphorylation of various 4E-BP1 residues [55].
When hypophosphorylated, the 4EBP1 binds tightly to eIF4E,
preventing proper formation of the eIF4 translation initiation
complex at the 5 end of cap-bearing mRNAs [56,57]. Hyperpho-
sphorylation of 4E-BP1 at Ser65 disrupts this interaction thus
eIF4E is released, allowing it to associate with eIF4G and other
relevant factors to promote cap-dependent translation [56,58]. In
our in vivo study, we showed that AICAR treatment induced the
activation of AMPK, and inhibited mTOR signaling indicated by
dephosphorylation of pS6RP (Ser235/236) and p4EBP-1 (Ser65)
in retinoblastoma tumor xenografts (Figure 5 A,B,D). Decreased
AMPK activation has been found in some cancers [59,60] and
mTOR signaling is has been activated many tumors [61], which
may become an attractive target for cancer therapy.
Progression of the cell cycle in eukaryotic cells is regulated by a
series of serine/threonine protein kinases which consist of a
catalytic subunit, cyclin dependent kinases (CDKs), and a
regulatory subunits, cyclins [35]. Whereas in our in vitro study
we observed changes in the mRNA levels of cyclins A, E and D
after AICAR administration, we did not observe any significant
differences after in vivo administration. In contrast our in vitro
findings of down regulation of p21 was also observed in the in vivo
study. Cdk-interacting protein 1 (Cip1 or p21) is a 21-kDa protein
known as inhibitor of cell cycle progression and tumor suppressor,
owing to its ability to inhibit the activity of CDK–cyclin complexes
and proliferating cell nuclear antigen (PCNA) [62–64]. Both our in
vitro and in vivo studies have seen a paradoxical down-regulation
of p21 in AICAR inhibited retinoblastoma. This paradoxical
down-regulation of p21 has not been reported in any previous
study of AICAR effects on cancer cells. Two possible explanations
are that either p21 was down-regulated as a compensatory
mechanism, or p21 acts as an oncogene in retinoblastoma cells.
Interestingly, p21 has been shown to be overexpressed in a variety
of human cancers including prostate, cervical, breast and
squamous cell carcinomas and, in many cases, p21 upregulation
correlates positively with tumor grade, invasiveness and aggres-
siveness and is a poor prognostic indicator [37]. Some recent
studies suggest that, under certain conditions and in some tumors,
p21 family can promote cellular proliferation, act as a positive
regulator of the cell cycle and inhibit apoptosis [37,65,66].
Interestingly, the studies of Gartel and Radhakrishnan [67]
suggest that p21 may act as a positive regulator of the cell cycle.
In fact, mitogenic stimuli result in transient p21 induction during
G1-S progression. Thus, when p21 is repressed in such a context,
it will lead to impairment of cell cycle progression due to decreased
complex formation of cyclin D-cdk4/cdk6. This may be one of the
mechanisms of AICAR inhibition of Rb cells and their arrest in S
phase. Together, these data suggest that depending on the cell
environment, p21 may function as either a tumor suppressor or an
oncogene and both our studies suggest that p21 may have a novel
function as an oncogene in human retinoblastoma tumor.
Our study demonstrates that AICAR significantly suppresses
the growth of retinoblastoma in vivo by apoptogenic and anti-
proliferative activity and is associated with decreased angiogenesis
and inhibition of macrophage infiltration (Fig. 6). We replicated in
vivo our in vitro finding of paradoxical down-regulation of p21 in
retinoblastoma after AICAR administration, which indicates that
p21 may have a novel function of an oncogene in retinoblastoma
tumor. The studies of AICAR’s anti-inflammatory properties
[43,44], exercise mimetic features [21], and anti-proliferative
effects in vitro and in vivo, provide a foundation for future clinical
strategies that utilize AICAR and AMPK activation by AICAR or
any other pharmacological agent as an attractive target for cancer
therapy as a single agent or in combination with other first-line
agents to improve treatment.
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